{
    "root": "8ebb7a30-d0c9-4604-b4ec-7fb3bba6cade",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sertraline Hydrochloride",
    "value": "20240401",
    "ingredients": [
        {
            "name": "SERTRALINE HYDROCHLORIDE",
            "code": "UTI8907Y6X"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "sertraline tablets indicated treatment following [ ( 14 ) ] : major depressive disorder ( mdd ) obsessive-compulsive disorder ( ocd ) panic disorder ( pd ) posttraumatic stress disorder ( ptsd ) social anxiety disorder ( sad ) premenstrual dysphoric disorder ( pmdd )",
    "contraindications": "­indication starting maximum mdd ( 2.1 ) 50 mg per day 200 mg per day ocd ( 2.1 ) 25 mg per day ( ages 6-12 ) 50 mg per day ( ages ≥ 13 ) 200 mg per day pd , ptsd , sad ( 2.1 ) 25 mg per day 200 mg per day pmdd ( 2.2 ) continuous dosing 50 mg per day 150 mg per day pmdd ( 2.2 ) intermittent dosing 50 mg per day luteal phase 100 mg per day luteal phase inadequate response starting , titrate 25-50 mg per day increments weekly mdd , ocd , pd , ptsd , sad ( 2.1 ) full prescribing information titration pmdd ( 2.2 ) hepatic impairment : mild : recommended starting maximum half recommended ( 2.4 ) moderate severe : recommended ( 2.4 ) discontinuing sertraline , reduce dose gradually ( 2.6 , 5.4 )",
    "warningsAndPrecautions": "sertraline 50 mg tablets : light blue film coated modified oval biconvex tablets debossed left side bisect g right side bisect one side “ 213 ” ndc 82009-049-05 bottles 500 sertraline 100 mg tablets : light yellow film coated modified oval biconvex tablets debossed left side bisect g right side bisect one side “ 214 ” ndc 82009-050-05 bottles 500 store 20°c 25°c ( 68°f 77°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "sertraline contraindicated patients : taking , within 14 days stopping , maois , ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.2 ) , ( 7.1 ) ] . taking pimozide [ ( 7.1 ) ] . known hypersensitivity sertraline ( e.g . , anaphylaxis , angioedema ) [ ( 6.1 , 6.2 ) ] .",
    "indications_original": "Sertraline tablets are indicated for the treatment of the following [See Clinical Studies (14)]:\n                  \n                     Major depressive disorder (MDD)\n                     Obsessive-compulsive disorder (OCD)\n                     Panic disorder (PD)\n                     Posttraumatic stress disorder (PTSD)\n                     Social anxiety disorder (SAD)\n                     Premenstrual dysphoric disorder (PMDD)",
    "contraindications_original": "­Indication Starting Dosage Maximum Dosage MDD ( 2.1 ) 50 mg per day 200 mg per day OCD ( 2.1 ) 25 mg per day (ages 6-12) 50 mg per day (ages ≥ 13) 200 mg per day PD, PTSD, SAD ( 2.1 ) 25 mg per day 200 mg per day PMDD ( 2.2 ) continuous dosing 50 mg per day 150 mg per day PMDD ( 2.2 ) intermittent dosing 50 mg per day during luteal phase only 100 mg per day during luteal phase only If inadequate response to starting dosage, titrate in 25-50 mg per day increments once weekly in MDD, OCD, PD, PTSD, and SAD ( 2.1 ) See Full Prescribing Information for titration in PMDD ( 2.2 ) Hepatic impairment: Mild: Recommended starting and maximum dosage is half recommended dosage ( 2.4 ) Moderate or severe: Not recommended ( 2.4 ) When discontinuing sertraline, reduce dose gradually ( 2.6 , 5.4 )",
    "warningsAndPrecautions_original": "Sertraline 50 mg Tablets: Light Blue film coated Modified oval biconvex tablets debossed with I on the left side of bisect and G on the right side of bisect on one side and “213” on other\n                  NDC 82009-049-05 Bottles of 500\n                  Sertraline 100 mg Tablets: Light Yellow film coated Modified oval biconvex tablets debossed with I on the left side of bisect and G on the right side of bisect on one side and “214” on other\n                  NDC 82009-050-05 Bottles of 500\n                  Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Sertraline is contraindicated in patients:\n                  \n                     Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [See Warnings and Precautions (5.2), Drug Interactions (7.1)]. \n                     \n                     Taking pimozide [See Drug Interactions (7.1)]. \n                     \n                     With known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema) [See Adverse Reactions (6.1, 6.2)]."
}